What Is Chronic Kidney Disease?

Chronic kidney disease, abbreviated CKD, is the persistent loss of kidney structure or function lasting three months or longer, defined by a glomerular filtration rate below 60 milliliters per minute per 1.73 square meters of body surface area, by markers of kidney damage such as albumin in the urine, or by both. The definition is deliberately functional rather than anatomical, because the kidneys perform several jobs at once: filtering nitrogenous waste, regulating fluid volume and electrolytes, controlling acid-base balance, producing erythropoietin, and activating vitamin D. Damage accumulates silently, and most people in the earlier stages have no symptoms at all.

Diabetes and hypertension cause the majority of cases worldwide, followed by glomerulonephritis, polycystic kidney disease, and obstructive uropathy. Once enough nephrons are lost, the survivors compensate by hyperfiltering, which raises glomerular pressure and accelerates scarring, so progression tends to continue even when the original insult is controlled. That self-reinforcing mechanism is why early detection and blood pressure management matter more to outcomes than any single therapy.

Staging and Measurement

The KDIGO classification, introduced in 2012 and retained in the 2024 guideline update, stages CKD on two axes. Filtration is graded G1 through G5, with G3 split into G3a and G3b, and albuminuria is graded A1 through A3 by urine albumin-to-creatinine ratio. A patient is described by both coordinates, since a person with normal filtration and heavy proteinuria faces a very different risk profile from one with reduced filtration and no albumin. The NIDDK quick reference on urine albumin-to-creatinine ratio and estimated GFR sets out the thresholds and the follow-up intervals each combination implies.

Glomerular filtration rate is almost never measured directly in routine care. It is estimated from serum creatinine, or from cystatin C, using regression equations such as the 2021 CKD-EPI formula, which removed the race coefficient present in earlier versions. Estimating equations carry known error, particularly at extremes of muscle mass, in acute illness, and in populations underrepresented in the derivation cohorts. A systematic review of GFR and albuminuria for detecting and staging kidney disease examined how well these markers perform across clinical contexts, and the residual uncertainty is a standing motivation for better point-of-care assays and continuous biomarker sensing.

Progression and End-Stage Kidney Disease

Falling filtration produces a predictable cascade of secondary disorders. Phosphate retention and reduced calcitriol drive secondary hyperparathyroidism and mineral bone disease, reduced erythropoietin causes anemia, potassium and acid accumulate, and cardiovascular risk rises steeply, so that most patients with moderate CKD die of cardiac causes before reaching dialysis. Clinical management, described in current reviews of chronic kidney disease, centers on renin-angiotensin system blockade, sodium-glucose cotransporter 2 inhibition, glycemic and blood pressure targets, and correction of the metabolic consequences. When filtration falls below roughly 15 milliliters per minute per 1.73 square meters, the disease is classified as end-stage kidney disease and survival requires renal replacement therapy.

Renal Replacement Technology

Dialysis is a mass transfer engineering problem. A hemodialyzer is a bundle of thousands of hollow semipermeable fibers with blood inside and dialysate flowing countercurrent outside, clearing small solutes by diffusion down concentration gradients and removing excess water by ultrafiltration under a pressure difference. Adequacy is quantified by Kt/V, the product of clearance and treatment time normalized to the volume of distribution of urea. Conventional in-center treatment runs about four hours three times a week, which is a coarse approximation of an organ that works continuously, and the resulting swings in volume and solute concentration drive much of the associated morbidity. Peritoneal dialysis uses the patient's own peritoneal membrane with cycler-controlled exchanges at home. Active research directions include sorbent-based dialysate regeneration to shrink water requirements, wearable and implantable devices, silicon nanopore membranes, and bioengineered kidney tissue. Transplantation remains the best outcome, and organ allocation, immunosuppression monitoring, and machine perfusion preservation are technical fields in their own right.

Applications

Chronic kidney disease research and care intersect with a range of technical fields, including:

• Membrane science and dialyzer design
• Biosensors and point-of-care assays for creatinine, cystatin C, and albumin
• Machine learning models for progression risk and acute deterioration alerts
• Medical imaging for renal volume, perfusion, and fibrosis assessment
• Wearable and implantable artificial organ development
• Health informatics and population screening program design